Dulaglutide Biosimilar, LY05008, Validated for Equivalent Efficacy and Safety in T2DM Treatment

Boan Biotech’s new biosimilar, LY05008, has been shown to have comparable efficacy and safety to its reference product, the widely used glucagon-like peptide-1 (GLP-1) receptor agonist dulaglutide (Trulicity). The findings, published in the Journal of Diabetes, are based on a phase 3 clinical trial in Chinese adults with type 2 diabetes mellitus (T2DM). This development is significant as it introduces a new, validated treatment option to the market.

Study Design and Key Findings

The study was a multicenter, randomized, open-label, active comparator phase 3 trial involving 440 Chinese adults with T2DM. Participants were randomly assigned to receive a 1.5-mg subcutaneous injection of either LY05008 or dulaglutide once per week for 24 weeks.

Primary Endpoint (HbA1c Reduction): The trial’s primary goal was to measure the change in hemoglobin A1c (HbA1c) from baseline to week 24. The results demonstrated equivalent efficacy between the two drugs. The mean change in HbA1c was approximately -1.44% for the LY05008 group and -1.41% for the dulaglutide group. This difference was not statistically significant.
Secondary Endpoints: The biosimilar also performed comparably across all secondary endpoints, including changes in:
- Body weight: Both groups experienced similar reductions.
- Fasting plasma glucose (FPG): The changes were comparable between the two groups.
- 2-hour postprandial plasma glucose (PPG): Reductions in PPG were similar for both treatments.

Safety and Tolerability

The safety and tolerability profiles of LY05008 were found to be highly similar to those of dulaglutide.

Common Adverse Events: The most frequently reported adverse effects in both groups were gastrointestinal, such as decreased appetite, diarrhea, nausea, and vomiting. These were predominantly mild to moderate in severity.
Hypoglycemia: Hypoglycemic events were rare in both groups.
Serious Adverse Events: The frequency of serious adverse events was comparable, with 4.1% in the LY05008 group and 3.7% in the dulaglutide group.

Implications for Diabetes Management

The successful validation of LY05008 as a biosimilar to dulaglutide provides a new, therapeutically equivalent option for diabetes management. This can potentially increase patient access and competition in the market for GLP-1 receptor agonists, which are crucial for improving glycemic control and reducing cardiovascular risk in patients with T2DM. The study authors concluded that “efficacy equivalence was achieved between LY05008 and dulaglutide with respect to change from baseline in HbA1C reduction to week 24,” confirming the biosimilar’s clinical viability.